SMAD3 and neoplasm: This gap warrants dedicated studies in these subgroups, especially since analyses of later-stage disease have revealed subtype-specific effects, such as HER2-driven SMAD3 phosphorylation, and our group and others have demonstrated that the tumor microenvironment carries distinct molecular characteristics and clinical value in the different subtypes [42, 51, 52].